Gemifloxacin mesylate (GFM) is a synthetic broad-spectrum antibacterial agent[1]. Gemifloxacin is a fluoroquinolone antibacterial agent which has an enhanced affinity for topoisomerase IV. It has potent activity against most gram-positive bacteria, particularly streptococcus pneumoniae. Gemifloxacin is over 30-fold more active than ciprofloxacin and 4- to 8-fold more active than moxifloxacin against this pathogen. Gemifloxacin has excellent activity against Haemophilus influenzae and Moraxella catarrhalis, and is unaffected by beta-lactamase production. Atypical respiratory pathogens (Legionella, Mycoplasma and Chlamydia spp.) are highly susceptible to gemifloxacin. Oral gemifloxacin 320 mg/day produced bacteriological responses of 94.7% in patients with acute exacerbations of chronic bronchitis and 95% of patients with uncomplicated urinary tract infections[3]. DTH (Delayed type hypersensitivity) assay has shown the significant immune suppressant potential of gemifloxacin at 25 mg/kg dose and 75mg/kg dose in mice[4]. Gemifloxacin is microbiologically the most active fluoroquinolone against Streptococcus pneumoniae--the leading pathogen of CAP (community-acquired pneumonia)[5].
United States, Alabama
... 展开 >>
University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama, United States, 35249-0001
United States, California
Los Angeles County Department of Public Health - Sexually Transmitted Disease Program
Los Angeles, California, United States, 90007-2608
San Francisco Department of Public Health - San Francisco City Clinic
San Francisco, California, United States, 94103-4030
United States, Maryland
Johns Hopkins Bayview Medical Center - Infectious Diseases
Baltimore, Maryland, United States, 21224-2735
United States, Pennsylvania
Magee Women's Hospital of UPMC - Reproductive Infectious Disease Research
Pittsburgh, Pennsylvania, United States, 15213-3108 收起 <<
搜索
